New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections

Future Microbiology

Volumn 3, Issue 6, 2008, Pages 635-648

  Waltes, Ken B ^a   Balish, Mitchell F ^b   Atkinson, T Prescott ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MIAMI UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Antimicrobial resistance; Asthma; Community acquired pneumonia; Cytadherence; Enzyme linked immunoassay; Mycoplasma pneumoniae; PCR

Indexed keywords

CIPROFLOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASTHMA; AUTOIMMUNITY; BACTERIAL STRAIN; CHRONIC LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; HOST; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; LABORATORY TEST; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; MICROBIOLOGY; MYCOPLASMOSIS; PATHOLOGY; PHYSIOLOGY;

MYCOPLASMA PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA;

EID: 59849114319     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.6.635     Document Type: Review

References (66)

1. Waites KB, Talkington DF: Mycoplasma-pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 17(4), 697-728 (2004).
2. Waldo RH 3rd, Krause DC: Synthesis, stability, and function of cytadhesin P1 and accessory protein B/C complex of Mycoplasma pneumoniae. J. Bacteriol. 188(2), 569-575 (2006).
3. Krause DC, Balish MF: Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae, Mol. Microbiol. 51(4), 917-924 (2004).
4. Balish MF: Subcellular structures of mycoplasmas. Front. Biosci. 11, 2017-2027 (2006).
5. Balish MF, Krause DC: Mycoplasmas: a distinct cytoskeleton for wall-less bacteria. J. Mol. Microbiol. Biotechnol. 11(3-5), 244-255 (2006).
6. Henderson GP, Jensen GJ: Three-dimensional structure of Mycoplasma pneumoniae's attachment organelle and a model for its role in gliding motility. Mol. Microbiol. 60(2), 376-385 (2006).
7. Sybert A, Herrmann R, Frangakis AS: Structural analysis of Mycoplasma pneumoniae by cryo-electron tomography. J. Struct. Biol. 156(2), 342-354 (2006).
8. Kenri T, Seto S, Horino A, Sasaki Y, Sasaki T, Miyata M: Use of fluorescent-protein tagging to determine the Subcellular localization of Mycoplasma pneumoniae proteins encoded by the cytadherence regulatory locus. J. Bacteriol. 186(20), 6944-6955 (2004).
9. Hasselbring BM, Krause DC: Proteins P24 and P41 function in the regulation of terminal-organelle development and gliding motility in Mycoplasma pneumoniae. J. Bacteriol. 189(20), 7442-7449 (2007).
10. Hasselbring BM, Krause DC: Cytoskeletal protein P41 is required to anchor the terminal organelle of the wall-less prokaryote Mycoplasma pneumoniae. Mol. Microbiol. 63(1), 44-53 (2007).
11. Hatchet JM, Balish MF: Attachment organelle ultrastructure correlates with phylogeny, not gliding motility properties, in Mycoplasma pneumoniae relatives. Microbiology 154(Pt 1), 286-295 (2008).
12. Seto S, Kenri T, Tomiyama T, Miyata M: Involvement of P1 adhesin in gliding motility of Mycoplasma pneumoniae as revealed by the inhibitory effects of antibody under optimized gliding conditions. J. Bacteriol. 187(5), 1875-1877 (2005).
13. Hasselbring BM, Jordan JL, Krause DC: Mutant analysis reveals a specific requirement for protein P30 in Mycoplasma pneumoniae gliding motility. J. Bacteriol. 187(18), 6281-6289 (2005).
14. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM: First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J. Clin. Microbiol. 45(11), 3534-3539 (2007).
15. Musatovova O, Kannan TR, Baseman JB: Genomic analysis reveals Mycoplasma pneumoniae repetitive element 1-mediated recombination in a clinical isolate. Infect. Immun. 76(4), 1639-1648 (2008).
16. Dumke R, Luck PC, Noppen C et al.: Culture-independent molecular subtyping of Mycoplasma pneumoniae in clinical samples. J. Clin. Microbiol. 44(7), 2567-2570 (2006).
17. Halbedel S, Hames C, Stulke J: In vivo activity of enzymatic and regulatory components of the phosphoenolpyruvate:sugar phosphotransferase system in Mycoplasma pneumoniae. J. Bacteriol. 186(23), 7936-7943 (2004).
18. Merzbacher M, Detsch C, Hillen W, Stulke J: Mycoplasma pneumoniae HPr kinase/phosphorylase. Eur. J. Biochem. 271(2), 367-374 (2004).
19. 2, a necessary evil for cell signaling. Science 312(5782), 1882-1883 (2006).
20. Kannan TR, Provenzano D, Wright JR, Baseman JB: Identification and characterization ot human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect. Immun. 73(5), 2828-2934 (2005).
21. Kannan TR, Baseman JB: ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc. Natl Acad. Sci. USA 103(17), 6724-6729 (2006).
22. May M, Papazisi L, Gorton TS, Geary SJ: Identification of fibronectin-binding proteins in Mycoplasma gallisepticum strain R. Infect. Immun. 74(3), 1777-1785 (2006).
23. Waites KB, Simecka JW, Talkington DF, Atkinson TP: Pathogensis of Mycoplasma pneumoniae infections: adaptive immunity, innate immunity, cell biology and virulence factors: In: Community-acquired Pneumonia. Suttorp N, Welte T, Marre R (Eds). Burkhauser Verlag, Basel, Switzerland, 183-199 (2007).
24. Meseguer MA, Alvarez A, Rejas MT, Sanchez C, Perez-Diaz JC, Baquero F: Mycoplasma pneumoniae: a reduced-genome intracellular bacterial pathogen. Infect. Genet. Evol. 3(1), 47-55 (2003).
25. Hoek KL, Duffy LB, Cassell GH, Dai Y, Atkinson TP: A role for the Mycoplasma pneumoniae adhesin P1 in interleukin (IL)-4 synthesis and release from rodent mast cells. Microb. Pathog. 39(4), 149-158 (2005).
26. Luo D, Dai Y, Duffy LB, Prescott Atkinson T: Inhibition of message for FcεRI α chain blocks mast cell IL-4 production induced by co-culture with Mycoplasma pneumoniae. Microb. Pathog. 44, 286-292 (2007).
27. Atkinson TP, Dai Y, Duffy I.B: Role of hydrogen peroxide in Mycoplasma pneumonia-induced mast cell IL-4 production. J. Allergy Clin. Immunol. 119, S54 (2007).
28. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA: Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr. Opin. Cell. Biol. 17(2), 183-189 (2005).
29. Luo D, Dai Y, Duffy I.B, Atkinson TP: Activation of the human monocytoid cell line THP-1 for cytokine production by Mycoplasma pneumoniae. J. Allergy Clin. Immunol. (2008) (in press).
30. Shimizu T, Kida Y, Kuwano K: Triacylated lipoproteins derived from Mycoplasma pneumoniae activate nuclear factor-κB through toll-like receptors 1 and 2. Immunology 121(4), 473-483 (2007).
31. Shimizu T, Kida Y, Kuwano K: A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-κB through TLR1, TLR2, and TLR6. J. Immunol 175(7), 4641-4646 (2005).
32. Shimizu T, Kida Y, Kuwano K: Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice. Infect. Immun. 76(1), 270-277 (2008).
33. Christie LJ, Honarmand S, Talkington DF et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 120(2), 305-313 (2007).
34. Waites KB, Duffy LB, Schwartz S, Talkington DF: Mycoplasma and ureaplasma. In: Clinical Microbiology Procedure Handbook. Isenberg (Ed.). American Society for Microbiology Press, Washington, DC, USA (2004).
35. Yuki N: Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 35(6), 691-711 (2007).
36. Ang CW, Tio-Gillen AP, Groen J et al.: Cross-reactive anti-galactocerebroside intibodies and Mycoplasma pneumoniae infections in Guillain-Barre syndrome. J.Neuroimmunol. 130(1-2), 179-183 (2002).
37. Narita M, Tanaka H, Togashi T, Abe S: Cytokines involved in CNS manifestations caused Mycoplasma pneumoniae. Pediatr. Neurol. 33(2), 105-109 (2005).
38. Stamm B, Moschopulos M, Hungerbuehler H, Guarner J, Genrich GL, Zaki SR: Neuroinvasion by Mycoplasma pneumoniae in acute disseminated encephalomyelitis. Emerg. Infect. Dis. 14(4), 641-643 (2008).
39. Ramirez AS, Rosas A, Hernandez-Beriain JA et al.: Relationship between rheumatoid arthritis and Mycoplasma pneumoniae: a case-control study. Rheumatology (Oxford) 44(7), 912-914 (2005).
40. Johnson SM, Bruckner F, Collins D: Distribution of Mycoplasma pneumoniae and Mycoplasma salivarium in the synovial fluid of arthritis patients. J. Clin. Microbiol. 45(3), 953-957 (2007).
41. Roediger WE: Intestinal mycoplasma in Crohn's disease. Novartis Found. Symp. 263, 85-93; discussion 93-98, 211-218 (2004).
42. Teig N, Anders A, Schmidt C, Riever C, Gatermann S: Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung disease. Thorax 60(11), 962-966 (2005).
43. Sutherland ER, Brandorff JM, Martin RJ: Atypical bacterial pneumonia and asthma risk. J. Asthma 41(8), 863-868 (2004).
44. Wu Q, Martin RJ, Lafasto S et al.: Toll-like receptor 2 down regulation in mouse allergic lungs decreases mycoplasma clearance. Am. J. Respir. Crit. Care Med. 177(7), 720-729 (2008).
45. Chaplin D, Zindl C, Duffy LB, Atkinson TP: Clearance of Mycoplasma pneumoniae is impaired in mice with established airway inflammation. J. Allergy Clin. Immunol. 119, S132 (2007).
46. Wu Q, Martin RJ, Rino JG, Breed R, Torres RM, Chu HW: IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes Infect. 9(1), 78-86 (2007).
47. + cells in lungs of mice. J. Allergy Clin. Immunol. 119, S156 (2007).
48. Martin RJ, Chu HW, Honour JM, Harbeck RJ: Airway inflammation and bronchial hyperresponsiveness, after Mycoplasma pneumoniae infection in a murine model. Am. J. Respir. Cell. Mol. Biol. 24(5), 577-582 (2001).
49. Atkinson TP, Duffy LB, Pendlev D. Dai Y, Cassell GH: Reduc ed IgG antibody to Mycoplasma pneumoniae among children with asthma: results of a five year study. J. Allergy Clin. Immunol. 115, S171 (2005).
50. Talkington DF, Short S, Fallon MT, Schwartz SB, Thacker WL: Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin. Diagn. Lab. Immunol. 11(5), 862-867, (2004).
51. Ozaki T, Nishimura N, Ahn J et al.: Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia ill children, and the antimicrobial susceptibility of the isolates. J. Infect. Chemother. 13(4), 204-207 (2007).
52. Csango PA, Pedersen JE, Hess RD.: Comparison of four Mycoplasma pneumoniae IgM-, IgG- and IgA-specific enzyme immunoassays in blood donors and patients. Clin Microbiol. Infect. 10(12), 1094-1098 (2004).
53. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H: Evaluation of 2 commercial test and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies with PCR used as the gold standard. J. Clin. Microbiol. 43(5), 2277-2285 (200).
54. Saito R, Misawa Y, Moriya K, Koike K, Obukata K, Okamura N: Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of Mycoplasma pneumoniae. J. Med. Microbiol. 54(Pt 11), 1037-1041 (2005).
55. Daxboeck F, Khanakah G, Bauer C, Stadler M, Hofmann H, Stanek G: Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR. Int. J. Med. Microbiol. 295(4), 279-285 (2005).
56. Michetow IC, Olsen K, Lozano J, Duffy LB, McCracken GH, Hardy RD: Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community acquired pneumonia. J. Clin. Microbiol. 42(7), 3339-3341 (2004).
57. Pitcher D, Chalker VJ, Sheppard C, George RC, Harrison TG: Real-time detection of Mycoplasma pneumonia in respiratory samples with an internal processing control. J. Med. Microbiol. 55(Pt 2), 149-155 (2006).
58. Raty R, Ronkko E, Kleemola M: Sample type is Crucial to the diagnosis of Mycoplasma pneumoniae pneumonia by PCR. J. Med. Microbiol. 54(Pt 3), 287-291 (2005).
59. Gruson D, Pereyre S, Renaudin H, Charron A, Bcbear C, Bebear CM: In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob. Agents Chemother. 49(3), 1190-1193 (2005).
60. Matsuoka M, Narita M, Okazaki N et al.: Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48(12), 4624-4630 (2004).
61. Suzuki S, Yamazaki T, Narita IM, et al.: Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob, Agents Chemother. 50(2), 709-712 (2006).
62. Morozumi M, Hasegawa K, Kobavashi R, et al.: Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49(6), 2302-2306 (200).
63. Morozumi M, Iwata S, Hasegawa K et al.: Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 52(1), 348-350 (2008).
64. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM: Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high resolution melt analysis. Antimicrob. Agents Chemother. 52, 3542-3549 (2008).
65. Waites KB, Duffy LB, Bebear CM et al.: Development of agar diution MIC quality control ranges for antimicrobials tested against Mycoplasma pneumoniae. Presented at: 16th Congress of the International Organization for Mycoplasmology. Cambridge, UK, 9-14 July (2006).
66. Waites KB, Duffy LB, Bebear CM et al.: Development of agar diution MIC quality control ranges for antimicrobials tested against Mycoplasma pneumoniae. Presented at: 16th Congress of the International Organization for Mycoplasmology. Cambridge, UK, 9-14 July (2006).